Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cellebrite DI (CLBT) Preferred Stock Liabilities (2019 - 2020)

Cellebrite DI has reported Preferred Stock Liabilities over the past 2 years, most recently at $101.2 million for Q4 2020.

  • Quarterly results put Preferred Stock Liabilities at $101.2 million for Q4 2020, changed 0.0% from a year ago — trailing twelve months through Dec 2020 was $101.2 million (changed 0.0% YoY), and the annual figure for FY2020 was $101.2 million, changed 0.0%.
  • Preferred Stock Liabilities for Q4 2020 was $101.2 million at Cellebrite DI, roughly flat from $101.2 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for CLBT hit a ceiling of $101.2 million in Q4 2019 and a floor of $101.2 million in Q4 2019.